Latest Property News

Queste Communications Ltd (ASX:QUE) posted a 66% increase in company-level profit for FY2026, but its consolidated entity, including Orion Equities (ASX:OEQ), saw earnings decline sharply amid weaker revenues and investment losses. No dividend was declared.

Orion Equities (ASX:OEQ) returned to profitability in FY26 with a $204,000 net profit, buoyed by a $400,000 uplift in investment property value. Despite a 7% dip in total revenue, net tangible asset backing per share edged up to $0.43, while no dividend was declared.

Castile Resources reveals a robust 2026 Scoping Study for its Rover 1 IOCG Project, projecting an 11-year underground mine life with five valuable metals driving strong economics and a staged development strategy.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Papyrus Australia has expanded its TBS contract for an additional sample run after mixed trial results and secured a $200,000 unsecured loan with Irwin Biotech, advancing its capital raising efforts with L39 Capital.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

Steamships Trading Company Limited saw a 14.3% revenue increase to K413.4 million in H1 2026, while net profit attributable to shareholders fell 12.2% to K21.8 million. Underlying profit rose 27.2% after adjusting for ERP expenses and insurance proceeds, with capital investment and cash flow both strengthening.

Dexus has delivered a 37.0 cents per security distribution for FY26, matching guidance despite economic headwinds, while initiating a strategic review of infrastructure funds acquired in 2023 and forecasting lower earnings in FY27.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Kyron Capital Group (ASX: KYN) reported a $51.9 million net loss for FY26, completing a $125 million recapitalisation to stabilise its balance sheet and reduce gearing. The Group's assets under management shrank to $1.8 billion following strategic divestments and mandate exits.

Kip McGrath Education Centres reversed prior losses with a $2.5 million profit in FY26 despite a 4.3% revenue dip driven by franchise consolidation and foreign exchange headwinds. The company declared a special dividend and faces an unsolicited $0.73 per share takeover offer.

Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.